Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease

Summary

Patients with end-stage renal disease (ESRD) have abnormalities in the cellular and plasmatic systems regulating blood homeostasis, which may contribute to their risk for thrombotic and bleeding complications. However, their relative contributions in this population are poorly understood. The aim of this study was to evaluate the distribution of enzymatic and cellular abnormalities in ESRD patients on haemodialysis as assessed by thromboelastography (TEG^®). Whole blood samples were analysed by TEG in ESRD patients (n=70) and in a control group (n=70) of subjects with coronary artery disease. Profiles were constructed considering the maximum amplitude (MA), a marker of platelet function, and reaction time (R), a marker of thrombin generation, values. R values were higher in ESRD patients compared with the control group (8.2 ± 2.8 vs. 5.7 ± 1.9 minutes [min], p <0.0001), while there were no differences in MA (66.7 ± 8.1 vs. 66.2 ± 6.6 mm, p=0.562). Nor mal manufacturer defined coagulation (2–8 min) and aggregation (51–69 mm) parameters were present in 31% of ESRD patients compared with 56% of controls (p=0.006). A hypocoagulable status was observed in 42.9% of ESRD patients compared with 8.9% in the control group (p<0.0001). There were no differences in platelet function, which showed a hyperaggregable status in 41.4% versus 35.7% of cases (p=0.603). Abnormalities in both parameters were observed in 15.7% of ESRD patients versus 1.4% in the control group (p = 0.004), which were more common among older patients (p= 0.005). In conclusion, patients with ESRD have an elevated prevalence of abnormal haemostatic profiles, which may contribute to their elevated risk of bleeding and thrombotic complications.

keywords

End stage renal disease - platelet function - coagulation

• References

• 1 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 5: 579-589.
• 2 Sohal AS, Gangji AS, Cowther MA. et al. Uremic bleeding: Pathophysiology and clinical risk factors. Thromb Res 2006; 118: 417-422.
• 3 Danechvar HL, Seddighzadeh A, Piazza G. et al. Deep venous thrombosis in patients with chronic kidney disease. Thromb Haemost 2008; 99: 1035-1039.
• 4 Di Benedetto A, Marcelli D, D’Andrea A. et al. Risk factors and underlying cardiovascular diseases in incident ESRD patients. J Nephrol 2005; 5: 592-598.
• 5 Gawaz MP, Dobos G, Spath HM. et al. Impaired function of platelet membrane glycoprotein Ilb/IIIa in end stage renal disease. J Am Soc Nephrol 1994; 5: 36-46.
• 6 Pawlak K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost 2009; 102: 49-55.
• 7 Vaziri ND, Gonzales EC, Wang J. et al. Blood coagulation, fibrinolytic and inhibitory proteins in end stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994; 6: 828-835.
• 8 Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103: 20A-26A.
• 9 Angiolillo DJ, Capranzano P, Desai B. et al. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 2009; 124: 318-322.
• 10 Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004; 2: 307-312.
• 11 Coresh J, Selvin E, Stevens LA. et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007; 298: 2038-2047.
• 12 Di Minno G, Martinez J, McKean ML. et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-559.
• 13 Eknoyan G, Brown CHD.. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-de- pendent adenosine triphosphatase. Am J Nephrol 1981; 1: 17-23.
• 14 Escolar G, Cases A, Bastida E. et al. Uremic platelets have a functional defect affecting the interaction of vonWillebrand factor with glycoprotein Ib. Blood 1990; 76: 1336-1340.
• 15 Roeloffzen WW, Kluin-Nelemans HC, Mulder AB. et al. Thrombocytopenia affects plasmatic coagulation as measured by thromboelastography. Blood Coagul Fibrinolysis 2010; 21: 389-397.
• 16 Henry P, Vermillet A, Boval B. et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011; 105: 336-344.
• 17 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 18 Agarwal AK, Patel BM, Haddad MJ. Central vein stenosis: a nephrologist’s perspective. Semin Dial 2007; 20: 53-62.
• 19 Nomura S. Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397-404.
• 20 Chou KJ, Jan CR, Lee PT. et al. Platelet hyperreactivity in hemodialysis patients with frequently occluded vascular access. Thromb Haemost 2004; 92: 621-626.
• 21 Demicheli M, Contino L, Iberti M. et al. Protein C and protein S levels in uremic patients before and after dialysis. Thromb Res 1992; 68: 451-453.
• 22 Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol 2010; 56: 1683-1692.
• 23 Gurbel PA, Bliden KP, Cohen E. et al. Race and sex differences in thrombogenicity: risk of ischemic events following stenting. Blood Coagul Fibrinolysis. 2008; 4: 268-275.
• 24 Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010; 104: 471-484.
• 25 Angiolillo DJ, Bernardo E, Capodanno D. et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146.